mRNA vaccine living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study

	COVID-19 severe or critically

	COVID-19 prophylaxis (excluding children)
mRNA vaccine	Tande Aleman Tenforde Lauring Fraiman CoVEHPI ... Chung Tenforde Shemer Boyarsky Shibli Thompson -VISIOn Network ... Thompson -VISIOn Network ... McMurry Mayo Clinic ... Nakahara McConeghy Accorsi Qatar ... EPIPHAR ... Kirsebom ... Thompson Agur Abu-Raddad
Comirnaty (tozinameran - Pfizer/BIONTECH)	Bernal ... Tenforde England ... Husby ... Weekes Palich Nanduri Kanokudom Shemer Chodcik Rozen-Zvi Haas Barda Sultan Shibli Dagan Yanay Heymann Coggiola Patone SIREN ... Haas Bjork Klein Watanabe Nguyen Scotland cohort Pawlowski Abu-Raddad EPI-PHARE Shasha BNT162b2 phase 3 ... Amit Goldberg Angel xie Patalon Zadok Wan South Africa ... Lustig Simpson ... Tartof
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)	Moderna study 201 100µg Southern California ... Benotmane Southern California ... Klein Pawlowski Husby ... COVE Moderna/NIH phase 3 ...

4888	study 101 dose finding, 2020	2	31	excluded	not a RCT	risk of bias not avaialble
6052	BioNTech phase 2 (Walsh), 2020	2	1	excluded		risk of bias not avaialble
6054	Moderna preclinical (Corbett), 2020	2	1	excluded		risk of bias not avaialble
6766	Pfizer 16-25 years phase 3, 0	2	1	excluded		risk of bias not avaialble
6966	Ou, 2021	2	32	excluded	not a RCT	risk of bias not avaialble
8248	Montgomery, 2021	2	13	excluded	not a RCT	risk of bias not avaialble
9065	Ruddy, 2021	2	32	excluded	not a RCT	risk of bias not avaialble
9445	Kawasuji, 2022	2	0	excluded		risk of bias not avaialble
9466	Falsey, 0	2	0	excluded		risk of bias not avaialble